Lonza Partners to Enter Probiotic Space

BASEL, Switzerland & BERLINLonza and ORGANOBALANCE signed a worldwide exclusive license agreement for Lonza to develop, produce and commercialize products containing a probiotic Lactobacillus strain. The patented strain, developed by ORGANOBALANCE, acts against Helicobacter pylori (H. pylori), a common bacterial infection that has been linked to peptic ulcers and gastritis, by binding to and effectively removing H. pylori from the stomach.

This agreement with ORGANOBALANCE creates a basis for Lonza to enter the probiotic marketa market with vast growth potentialwith a unique ingredient," said Roman Quinter, senior vice president and head of the Nutrition Ingredients business for Lonza. Lonza is a global leader in the manufacturing of intermediates and APIs for the pharmaceutical industry through biotechnology and fermentation. Integrating the Lactobacillus anti-H. pylori strain into our nutrition ingredient portfolio provides an opportunity to leverage our strong biotech expertise and knowledge to provide a highly effective product to the nutrition landscape.

Christine Lang, Ph.D., CEO of ORGANOBALANCE, added: As the leader in the development of innovative probiotic strains, we regard this agreement with Lonza as a further recognition of ORGANOBALANCEs strategy, our expertise, and our innovative capacity. We highly appreciate Lonzas dedication to lead our development into great success on the nutrition marketplace."